|
Lymphoid Neoplasia
Citations 211-220 of 299 total displayed.
|
Past content
(since Jan 2009):
|
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation
- Deepa Sampath, George A. Calin, Vinay K. Puduvalli, Gopal Gopisetty, Cristian Taccioli, Chang-Gong Liu, Brett Ewald, Chaomei Liu, Michael J. Keating, and William Plunkett
Blood 2009; 113: 3744-3753.
[Abstract]
[Full text]
[PDF]
Differentiation stage–specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas
- Raquel Malumbres, Kristopher A. Sarosiek, Elena Cubedo, Jose W. Ruiz, Xiaoyu Jiang, Randy D. Gascoyne, Robert Tibshirani, and Izidore S. Lossos
Blood 2009; 113: 3754-3764.
[Abstract]
[Full text]
[PDF]
Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
- David Daydé, David Ternant, Marc Ohresser, Stéphanie Lerondel, Sabrina Pesnel, Hervé Watier, Alain Le Pape, Pierre Bardos, Gilles Paintaud, and Guillaume Cartron
Blood 2009; 113: 3765-3772.
[Abstract]
[Full text]
[PDF]
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
- Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen Leach, Angela Brooks-Wilson, Laurie H. Sehn, Mukesh Chhanabhai, Ryan R. Brinkman, Joseph M. Connors, Andrew P. Weng, and Randy D. Gascoyne
Blood 2009; 113: 3773-3780.
[Abstract]
[Full text]
[PDF]
Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks
- Enrique M. Ocio, Patricia Maiso, Xi Chen, Mercedes Garayoa, Stela Álvarez-Fernández, Laura San-Segundo, David Vilanova, Lucía López-Corral, Juan C. Montero, Teresa Hernández-Iglesias, Enrique de Álava, Carlos Galmarini, Pablo Avilés, Carmen Cuevas, Jesús F. San-Miguel, and Atanasio Pandiella
Blood 2009; 113: 3781-3791.
[Abstract]
[Full text]
[PDF]
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
- John E. Weldon, Laiman Xiang, Oleg Chertov, Inger Margulies, Robert J. Kreitman, David J. FitzGerald, and Ira Pastan
Blood 2009; 113: 3792-3800.
[Abstract]
[Full text]
[PDF]
miR-34a as part of the resistance network in chronic lymphocytic leukemia
- Thorsten Zenz, Julia Mohr, Eric Eldering, Arnon P. Kater, Andreas Bühler, Dirk Kienle, Dirk Winkler, Jan Dürig, Marinus H. J. van Oers, Daniel Mertens, Hartmut Döhner, and Stephan Stilgenbauer
Blood 2009; 113: 3801-3808.
[Abstract]
[Full text]
[PDF]
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab
- Shannon P. Hilchey, Ollivier Hyrien, Tim R. Mosmann, Alexandra M. Livingstone, Jonathan W. Friedberg, Faith Young, Richard I. Fisher, Raymond J. Kelleher, Jr, Richard B. Bankert, and Steven H. Bernstein
Blood 2009; 113: 3809-3812.
[Abstract]
[Full text]
[PDF]
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
- Leandro C. Cerchietti, Shao Ning Yang, Rita Shaknovich, Katerina Hatzi, Jose M. Polo, Amy Chadburn, Steven F. Dowdy, and Ari Melnick
Blood 2009; 113: 3397-3405.
[Abstract]
[Full text]
[PDF]
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
- Heinz Ludwig, Roman Hajek, Elena Tóthová, Johannes Drach, Zdenek Adam, Boris Labar, Miklós Egyed, Ivan Spicka, Heinz Gisslinger, Richard Greil, Ingrid Kuhn, Niklas Zojer, and Axel Hinke
Blood 2009; 113: 3435-3442.
[Abstract]
[Full text]
[PDF]
|
|
